Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388506 | 0.86 | ADRA2A (0.44) | CYP19A1CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL14309671 | 0.83 | CHRNB2 (0.38) | CYP19A1CYP11B1CYP11B2DRD2DRD3 | |
| SCHEMBL6389933 | 0.80 | HTR2A (0.52) | CYP19A1CYP11B2CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6387593 | 0.77 | KDM4C (0.34) | CYP19A1CYP11B1CYP11B2KDM4CCHRNB2 | |
| SCHEMBL4238327 | 0.74 | TYMS (0.37) | CYP19A1CYP11B1CYP11B2DRD2DRD3 | |
| SCHEMBL6385691 | 0.70 | HTR2A (0.52) | CYP19A1CYP11B2 | |
| SCHEMBL6388288 | 0.70 | CYP19A1 (0.47) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6391836 | 0.69 | CYP11B1 (0.44) | CYP19A1CYP11B1CYP11B2KDM4C | |
| SCHEMBL6391832 | 0.69 | CYP11B1 (0.44) | CYP19A1CYP11B1CYP11B2KDM4C | |
| SCHEMBL14415681 | 0.66 | HTR2A (0.60) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | CYP19A1 763/4885CYP11B1 500/4885CYP11B2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.